HC Wainwright restated their buy rating on shares of SAB Biotherapeutics (NASDAQ:SABS – Free Report) in a research report report published on Monday morning, Benzinga reports. HC Wainwright currently has a $10.00 target price on the stock, up from their previous target price of $1.00. HC Wainwright also issued estimates for SAB Biotherapeutics’ Q4 2023 […]
/PRNewswire/ The "Global Antibody Hit Generation and Screening Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com s.
SAB Biotherapeutics, Inc. (NASDAQ:SABSW – Get Free Report) saw a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 1,300 shares, a drop of 71.7% from the November 15th total of 4,600 shares. Based on an average daily trading volume, of 4,200 shares, the days-to-cover […]
SAB Biotherapeutics (NASDAQ:SABS – Get Free Report) and MiNK Therapeutics (NASDAQ:INKT – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends. Analyst Ratings This is a summary of […]
SAB Biotherapeutics, Inc. (NASDAQ:SABS – Get Free Report) saw a significant drop in short interest in the month of September. As of September 15th, there was short interest totalling 306,500 shares, a drop of 17.5% from the August 31st total of 371,600 shares. Based on an average daily volume of 35,900 shares, the short-interest ratio […]